Abstract: An isotopic tracer composition and methods of making and using same for radiological evaluation of body functions and diseases in a subject and for radiological therapy. The isotopic tracer composition comprises a protein carrier agent such as fibrinogen, antibodies, enzymes or portions thereof, bound to a radioisotope which has been reduced to a lower oxidation state by stannous phosphate at a pH of greater than 7. Some suitable radioisotopes are isotopes of technetium, rhenium and ruthenium.

Abstract: Taxol and radiolabelled taxol are produced from sterilized Yew trees by contacting sterilized Yew tree stock with a reactor solution comprising a reducing agent, an energy source, a buffer to maintain pH in the range of 6.5 to 7.5, a taxol precursor, and a steroid inhibitor. A radiolabelled precursor may be included in the reactor solution to produced radiolabelled taxol.

Abstract: This invention relates to the preparation and use of novel open-chain or cyclic polypeptide constructs in which two or more polypeptide chains, in an open-chain construct, or one or more chains, in a cyclic construct, are chemically derivatized such that the resulting construct exhibits both metal-binding capability and tissue-, organ- or cell-targeting selectivity. In particular, the polypeptide constructs of the present invention comprise compounds of the formula (I): ##STR1## in which, "B" is a hydrocarbon backbone, "P" is a polypeptide capable of targeting particular cells, tissues or organs of the body, "A" may be the group --NR'--NR"-- or the group --NR'--NR"--L-- in which L may be an aliphatic or aromatic linker group, R, R' and R" may be the same or different and may be hydrogen or an aliphatic group, m is an integer .gtoreq.2, provided that the groups R, R', R', L and "P" of a given chain may be the same or different from the groups R, R', R", L and "P" of another chain, n is an integer .gtoreq.

Abstract: This invention relates to novel dopamine D-1 and D-2 imaginging agents which are both fluorinated and iodinated and can appropriately labelled for use in both PET and SPECT imaging. Compounds include S-(-)-2-fluoroethoxy-3-methyl-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-iodoben zamide and R(+)-2,3-dimethoxy-N-[(1-(4'-fluorobenzyl)-2-pyrrolidinyl)methyl]-5-iodobe nzamide.

Abstract: Taxol and radiolabelled taxol are produced from sterilized Yew trees by contacting sterilized Yew tree stock with a reactor solution comprising a taxol precursor under a reducing environment. The reactor solution may also contain a reducing agent, an energy source, a buffer to maintain pH in the range of 6.0 to 8.0, and a steroid inhibitor. A radiolabelled precursor may be included in the reactor solution to produced radiolabelled taxol.

Abstract: The invention relates to radiolabeled imaging of a mammalian body. The invention in particular provides for reagents labeled with technetium-99m for such imaging. The invention provides peptides which bind Tc-99m and which can be targeted to specific sites within a mammalian body.

Abstract: Peptides containing a biological-function domain and a medically useful metal ion-binding domain are labeled with medically useful metal ions for use in diagnosis and treatment of a variety of pathologic conditions. The peptides have the amino acid sequence(R.sub.1)-[Y.sub.1 ].sub.n -(R.sub.2),(R.sub.1)-[Y.sub.1 -(R.sub.2)-Y.sub.1 ].sub.n -(R.sub.3)and (R.sub.1)-[Y.sub.1 -(R.sub.2)-Y.sub.2 ].sub.n -(R.sub.3)wherein the medically useful metal ion-binding domain is [Y.sub.1 ].sub.n, [Y.sub.1 -(R.sub.2)-Y.sub.1 ].sub.n or [Y.sub.1 -(R.sub.2)-Y.sub.2 ].sub.n in which n is a number between 1 and about 6 and Y.sub.1 and Y.sub.2 are amino acids with a sulfur, nitrogen or oxygen which is available for binding to metal ions, or can be made available for binding to metal ions; the biological-function domain is an amino acid sequence containing from 1 to about 20 amino acids located in any one or more of R.sub.1, R.sub.2 or R.sub.3 ; and those portions of R.sub.1, R.sub.2 and R.sub.

Abstract: Methods for the preparation and use of a biological delivery system are disclosed. The method of preparation includes the loading of a non-biological material into a biostructure having a load-bearing structure. The method also includes the removal of some of the biostructure's contents and the loading of a non-biological material into the biostructure. The biostructure is biologically compatible with the host, and preferably is derived from the host, the host's species or a related species. The loaded biostructure is used directly, or it can be targeted to specific cells, tissues and/or organs within a host. The targeted biostructure can be used to deliver the non-biological material to a specified tissue, organ or cell within a host for diagnostic, therapeutic or other purposes.

Abstract: A method is provided for delivering micellular particles containing chemotherapeutic agents and a marker to tumors within a body for the diagnosis and treatment of such tumors. The micellular particles are small, less than 2000 .ANG. and incorporate pure, neutral phospholipid molecules in their external surface. Enhanced delivery of the micellular particles containing marker and chemotherapeutic agents may be achieved by introducing an initial group of positively charged micellular particles to block the reticuloendothelial cells present in the body.

Abstract: An iodinated neuroprobe is provided for mapping monoamine reuptake sites. The iodinated neuroprobe is of the formula: ##STR1## wherein R=a C.sub.n H.sub.2n+1 group where n=0-6, an alkenyl group, a monofluoroalkyl group including .sup.n F where n=18 or 19, or a .sup.m C.sub.n H.sub.2n+1 group where n=1-6 and where m=11 or 14 for at least one .sup.m C;R'=a C.sub.n H.sub.2n+1 group where n=0-6, a p-iodophenylmethyl group, a p-iodophenylethyl group, a phenylmethyl group, or a phenylethyl group;X=an isotope of F, an isotope of Cl, an isotope of Br, an isotope of I, CH.sub.3, or Sn(R".sub.1 R".sub.2 R".sub.3);R".sub.1 =a C.sub.n H.sub.2n+1 group where n=1-6, or an aryl group;R".sub.2 =a C.sub.n H.sub.2n+1 group where n=1-6, or an aryl group;R".sub.3 =a C.sub.n H.sub.2n+1 group where n=1-6, or an aryl group; andY=H only if X is an isotope of I, or R' is a p-iodophenylmethyl group, or R' is a p-iodophenylethyl group, else Y=an isotope of I.Related analogs are also provided.

Abstract: A polyspecific anti-leukocyte antibody conjugate for targeting foci of leukocyte accretion comprises an immunoreactive polyspecific composite of at least two different substantially monospecific antibodies or antibody fragments, conjugated to at least one imaging agent, wherein at least two of said antibodies or antibody fragments specifically bind to different leukocyte cell types.A method for targeting an imaging agent to an inflammatory or infectious lesion comprises injecting a mammal parenterally with an effective amount for targeting of the above anti-leukocyte imaging conjugate.A therapeutic anti-leukocyte antibody-agent conjugate for targeting foci of leukocyte accretion comprises at least one immunoreactive substantially monospecific antibody or antibody fragment which specifically binds to at least one leukocyte cell type, conjugated to at least one therapeutic antimicrobial agent and/or radionuclide.

Abstract: Micellular particles such as small unilamellar vesicles of less than 2000 .ANG. loaded with .sup.111 In are administered to BALB/c mice in which EMT6 tumors had been induced. Whole body scintographs of the mice to which either neutral or positively or negatively charged vesicles had been administered show a substantial quantity of the vesicle entrapped .sup.111 In localized in the tumor. Blocking of macrophages in the liver and spleen by first administering unlabeled, aminomannose substituted vesicles before administration of the labeled vesicles increases uptake of the .sup.111 In labeled vesicles in the tumor.

Abstract: The present invention provides metal chelating compounds, to chelates and chelate-targeting agent conjugates formed from the chelating compounds, and to methods for making and using these compositions. The chelating compounds incorporate two nitrogen atoms and three sulfur atoms ("N.sub.2 S.sub.3 "), two nitrogen atoms and four sulfur atoms ("N.sub.2 S.sub.4 "), or three nitrogen atoms and three sulfur atoms ("N.sub.3 S.sub.3 "). Metals, and metal oxides, capable of being chelated by the compounds include those that are radionuclides, such as .sup.99m Tc and .sup.186/188 Re.The targeting agent portion of the chelate-targeting agent conjugates provided includes antibodies, peptides, hormones, enzymes and biological response modifiers. Methods for making the conjugates are provided and encompass the addition of a metal, or metal oxide, to a chelating compound prior to attachment to a targeting agent as well as subsequent to the attachment.

Abstract: A method for detection and localization of tissues having estrogen receptors during surgery is disclosed. The method involves administering an effective amount of an estradiol derivative labeled with a radionuclide to a patient and then delaying surgery for a time interval for permitting the labeled estradiol derivative to localize in the tissue. Thereafter, an operative field of the animal is surgically accessed an the tissue within the operative filed examined with a probe to detect photon emission from the labeled estradiol derivative.

Abstract: Complexes of bicyclopolyazamacrocyclophosphonic acid compounds with a metal ion, e.g. .sup.153 Sm, .sup.177 Lu, .sup.159 Gd, .sup.149 Pm, .sup.140 La, .sup.175 Yb, .sup.166 Ho, .sup.90 Y, .sup.47 Sc, .sup.186 Re, .sup.188 Re, .sup.142 Pr, .sup.99m Tc, .sup.67 Ga, .sup.68 Ga, .sup.105 Rh, .sup.97 Ru, .sup.111 In, .sup.113m In or .sup.115m In ion, are disclosed. The complexes can be covalently attached to a biologically active molecule, e.g. an antibody or antibody fragment, to form conjugates. The complexes and conjugates are useful as radiopharmaceutical agents for therapy and/or diagnostic purposes.

Abstract: A simple method for the synthesis of 1,4,7,10-tetraazacyclododecane N,N'N",N'"-tetraacetic acid and 1,4,8,11-tetraazacyclotetradecane N,N',N",N'"-tetraacetic acid involves cyanomethylating 1,4,7,10-tetraazacyclododecane or 1,4,8,11-tetraazacyclotetradecane to form a tetranitrile and hydrolyzing the tetranitrile. These macrocyclic compounds are functionalized through one of the carboxylates and then conjugated to various biological molecules including monoclonal antibodies. The resulting conjugated molecules are labeled with radiometals for SPECT and PET imaging and for radiotherapy.

Abstract: A 4-quinolone antibiotic compound is used in gamma ray scintigraphy diagnostic imaging of a patient with a metallic radionuclide so as to locate focal infection.

Abstract: The present invention relates to novel technetium-99m complexes and to methods of preparing the complexes. The present invention further relates to a radiopharmaceutical compositions comprising the complexes, to the use of the compositions for examining the renal function, and to a kit for preparing such compositions.

Abstract: A method of imaging a target site in an animal's body in which a labelled CC chemokine or Monocyte Attractant Protein (MCP) material is introduced into the animal's body and allowed to accumulate at a target site which includes MCP receptor molecules. The accumulated, labelled MCP material is then detected so as to image the target site of the body.

Abstract: Analogs of cytochalasin B are used as radiopharmaceuticals to provide an image for the nuclear imaging of glucose transport across cell membranes. Like cytochalasin B, the analogs bind specifically to glucose transport protein, and in doing so, serve as markers indicating the amount of glucose transport protein present on the surfaces of cells. The analogs differ from cytochalasin B by the inclusion of a radionuclide in the region of the terminal phenyl group on cytochalasin B, where the radionuclide does not interfere with the binding specificity of the analog. Disclosed herein are such analogs as well as analogs with which readily accept radionuclides at the desired location on the structure, either by conjugation or substitution.